利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

242 条记录 (耗时 0.024 秒)

    Oxazolidinedione derivatives and their use
    1.
    发明授权
    Oxazolidinedione derivatives and their use 失效
    恶唑二酮衍生物及其用途

    公开(公告)号：US5614544A

    公开(公告)日：1997-03-25

    申请号：US303209

    申请日：1994-09-08

    申请人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose

    发明人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose

    IPC分类号： C07D263/44 ,  C07D413/14 ,  C07D417/10 ,  A61K31/42

    CPC分类号： C07D263/44 ,  C07D413/14 ,  C07D417/10

    摘要： [Object]To provide a new 2,4-oxazolidinedione derivative possessing excellent hypoglycemic and hypolipidemic activities.[Constituent]A 2,4-oxazolidinedione derivative represented by the general formula: ##STR1## wherein X represents --CH.sub.2 --, --C(.dbd.O)--, --CH(OH)--, --C(.dbd.NOH)-- or --CH.dbd.CH--; R represents a hydrocarbon residue or heterocyclic group which may be substituted; n represents an integer from 0 to 5, and m represents an integer from 1 to 3; ....... represents a single or double bond; provided that n is an integer from 1 to 5 when X is --C(.dbd.O)--, or a pharmacologically acceptable salt thereof.[Drawings selected]None

    摘要翻译： [目的]提供具有优异的降血糖和降血脂活性的新的2,4-恶唑烷二酮衍生物。 [组成成分]下列通式表示的2,4-恶唑烷二酮衍生物：其中X代表-CH2-，-C（= O） - ， - CH（OH） - ， - C（= NOH） CH = CH-; R表示可以被取代的烃残基或杂环基; n表示0〜5的整数，m表示1〜3的整数， + E，uns ....... + EE表示单键或双键; 条件是当X为-C（= O） - 时，n为1至5的整数，或其药理学上可接受的盐。 [已选图纸]无

    Oxazolidinedione derivatives and their use
    2.
    发明授权
    Oxazolidinedione derivatives and their use 失效
    恶唑二酮衍生物及其用途

    公开(公告)号：US06552058B1

    公开(公告)日：2003-04-22

    申请号：US09667247

    申请日：2000-09-22

    申请人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose ,  Sachiko Imai

    发明人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose ,  Sachiko Imai

    IPC分类号： C07D26318

    CPC分类号： C07D263/44 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

    摘要： Novel 2,4-oxazolidinedione compounds of the formula: wherein R is a hydrocarbon residue or a heterocyclic group each of which may be substituted; Y is —CO—, —CH(OH)— or —NR3— (wherein R3 is an alkyl group which may be substituted); m is 0 or 1; n is 0, 1 or 2; X is CH or N; A is bivalent straight or branched hydrocarbon chain residue having 1 to 7 carbon atoms; R1 and R2 each are hydrogen or an alkyl group, or R1 and R2 are combined with each other to form a 5- to 6-membered heterocyclic group optionally containing nitrogen; L and M each are hydrogen, or L and M are combined with each other to form a bond, or pharmaceutically acceptable salts thereof, having excellent hypoglycemic and hypolipidemic activities and are useful as anti-diabetics or hypolipidemic agents.

    摘要翻译： 下式的新型2,4-恶唑烷二酮化合物：其中R是可以被取代的烃残基或杂环基; Y是-CO - ， - CH（OH） - 或-NR 3 - （其中R 3是可被取代的烷基）; m为0或1; n为0,1或2; X是CH或N; A是具有1至7个碳原子的二价直链或支链烃链残基; R 1和R 2各自为氢或烷基，或者R 1和R 2彼此结合形成任选含有氮的5至6元杂环基; L和M各自为氢，或L和M彼此结合以形成具有优异的降血糖和降血脂活性的键或其药学上可接受的盐，并且可用作抗糖尿病药或降血脂药。

    Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
    4.
    发明授权
    Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents 失效
    恶唑化合物及其作为抗糖尿病和骨抑制剂的用途

    公开(公告)号：US5239080A

    公开(公告)日：1993-08-24

    申请号：US723675

    申请日：1991-06-27

    申请人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose

    发明人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose

    IPC分类号： C07D263/32

    CPC分类号： C07D263/32

    摘要： Oxazole compounds having the formula: ##STR1## in which A is a group of the formula --CH.sub.2 OR.sup.3 (R.sup.3 is a hydrogen atom, an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an acyl group), or an aldehyde group and B is an optionally substituted phenyl group, or their salts, which are useful as antidiabetic agents.

    摘要翻译： 具有下式的恶唑化合物：其中A是式-CH 2OR 3的基团（R 3是氢原子，任选取代的烃残基，任选取代的杂环基或酰基）或醛 基团，B是任选取代的苯基或其盐，其可用作抗糖尿病剂。

    Thiazolidinedione derivatives, their production and use
    7.
    发明授权
    Thiazolidinedione derivatives, their production and use 失效
    噻唑烷二酮衍生物，其生产和使用

    公开(公告)号：US5489602A

    公开(公告)日：1996-02-06

    申请号：US376529

    申请日：1995-01-23

    申请人： Takashi Sohda ,  Hitoshi Ikeda ,  Sachiko Imai ,  Yu Momose

    发明人： Takashi Sohda ,  Hitoshi Ikeda ,  Sachiko Imai ,  Yu Momose

    IPC分类号： A61K31/44 ,  A61K31/427 ,  A61K31/4427 ,  A61K31/4439 ,  A61P3/06 ,  A61P3/08 ,  A61P3/10 ,  C07D213/00 ,  C07D249/00 ,  C07D277/00 ,  C07D277/34 ,  C07D413/12 ,  C07D417/14

    CPC分类号： C07D413/12 ,  C07D417/14

    摘要： The object of the present invention is to provide a new thiazolidinedione derivative exhibiting excellent hypoglycemic and hypolipidemic action.Thiazolidinedione derivative represented by the general formula: ##STR1## wherein n represents an integer from 1 to 3; A represents an aromatic 5-membered heterocyclic ring residue which has at least one nitrogen atom as a ring component atom, which is bound via a carbon atom adjacent to the nitrogen atom and which may be substituted; .cndot..cndot..cndot..cndot..cndot..cndot..cndot..cndot. is a single bond or a double bond, or pharmacologically acceptable salt thereof, is novel, and shows excellent hypoglycemic and hypolipidemic action.

    摘要翻译： 本发明的目的是提供一种显示出优异的降血糖和降血脂作用的新的噻唑烷二酮衍生物。 由以下通式表示的噻唑烷二酮衍生物：其中n表示1至3的整数; A表示具有至少一个氮原子作为环成分原子的芳族5元杂环残基，其通过与氮原子相邻的碳原子结合并且可被取代; ........是单键或双键，或其药理学上可接受的盐，是新颖的，并且显示出优异的降血糖和降血脂作用。

    Age formation inhibitors
    9.
    发明授权
    Age formation inhibitors 失效
    年龄形成抑制剂

    公开(公告)号：US5302608A

    公开(公告)日：1994-04-12

    申请号：US71036

    申请日：1993-06-02

    申请人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose

    发明人： Takashi Sohda ,  Hitoshi Ikeda ,  Yu Momose

    IPC分类号： C07D277/48 ,  C07D417/04 ,  C07D417/12 ,  A61K31/425

    CPC分类号： C07D417/04 ,  C07D277/48 ,  C07D417/12

    摘要： Thiourea compounds represented by the general formula: ##STR1## wherein A is an aromatic ring group which may be substituted; R.sup.1 is a hydrogen atom or a lower alkyl or aryl group which may be substituted, or may combine with A to form a cyclic ring; and --COB is an acyl group of a carboxylic acid or an esterified carboxyl group or salts thereof are provided as agents for inhibiting the formation of AGE (Advanced Glycosidation End Product), which are employable for treating diseases caused by AGE-formation, such as diabetic complications, senile cataract, atherosclerosis etc.

    摘要翻译： 由以下通式表示的硫脲化合物：其中A是可被取代的芳环基团; R1是氢原子或可被取代的低级烷基或芳基，或可以与A结合形成环状环; 提供-COB为羧酸或酯化羧基的酰基或其盐作为用于抑制AGE（Advanced Glycosidation End Product）形成抑制剂的药剂，其可用于治疗由AGE形成引起的疾病，例如 糖尿病并发症，老年性白内障，动脉粥样硬化等。